Acrivon Therapeutics
ACRV
40 hedge funds and large institutions have $196M invested in Acrivon Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 39 → 40 (+1)
3% more capital invested
Capital invested by funds: $191M → $196M (+$4.98M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.44% less ownership
Funds ownership: 69.42% → 68.98% (-0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.21M |
| 2 |
BlackRock
New York
|
+$716K |
| 3 |
State Street
Boston,
Massachusetts
|
+$492K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$311K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.74M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$409K |
| 3 |
D.E. Shaw & Co
New York
|
-$181K |
| 4 |
Goldman Sachs
New York
|
-$174K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$71.9K |
ACRV Hedge Fund Activity: Q2 2023 in Review
40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q2 2023, worth a combined $196M — up 2.6% from $191M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ACRV positions and 4 closed out — a net gain of 1 holder — while 17 added to existing stakes and 11 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $1.21M. The largest seller was Federated Hermes, cutting an estimated $3.74M.
- 40 institutional investors held Acrivon Therapeutics (ACRV) as of Q2 2023, up from 39 in Q1 2023.
- Funds reported $196M of Acrivon Therapeutics stock for Q2 2023, up 2.6% quarter-over-quarter.
- 5 funds opened new Acrivon Therapeutics positions in Q2 2023 and 4 closed out, a net change of +1 holder.
- The largest Acrivon Therapeutics buyer in Q2 2023 was UBS O'Connor, an estimated $1.21M added.
- The largest Acrivon Therapeutics seller in Q2 2023 was Federated Hermes, an estimated $3.74M sold.
Based on aggregated 13F filings for Q2 2023.